References
- Haleblian JK, McCrone W. Pharmaceutical applications of polymorphism. J Pharm Sci 1969;58:911–929.
- Stephenson GA, Forbes RA, Reutzel-Edens SM. Characterization of the solid state: Quantitative issues. Adv Drug Deliv Rev 2001;48:67–90.
- Zhang GGZ, Law D, Schmitt EA, Qui Y. Phase transformation considerations during process development and manufacture of solid oral dosage forms. Adv Drug Deliv Rev 2004;56:371–390.
- Vippagunta SR, Brittain HG, Grant DJ. Crystalline solids. Adv Drug Deliv Rev 2001;48:3–26.
- Kustrin SA, Wu V, Rades T, Saville D, Tucker IG. Powder diffractometric assay of two polymorphic forms of ranitidine hydrochloride. Int J Pharm 1999;184:104–114.
- Tiwari M, Chawla G, Bansal AK. Quantification of olanzapine polymorphs using powder X-ray diffraction technique. J Pharm Biomed Anal 2007;43:865–872.
- Chieng N, Rehder S, Saville D, Rades T, Aaltonen J. Quantitative solid-state analysis of three solid forms of ranitidine hydrochloride in ternary mixtures using Raman spectroscopy and X-ray powder diffraction. J Pharmaceut Biomed Analysis 2009;49:18–25.
- Hursta VJ, Schroeder PA, Styron RW. Accurate quantification of quartz and other phases by powder X- ray diffractrometry. Anal Chimica Acta 1997;337:233–252.
- Jarvis B, Simpson K. Clopidogrel: A review of its use in the prevention of atherothrombosis. Drugs 2000;60:347–377.
- Bousquet A, Castro B, Saint-Germain J. Polymorphic form of clopidogrel hydrogen sulphate; US Patent 6504030; (2003).
- Koradia V, Chawla G, Bansal AK. Qualitative and quantitative analysis of clopidogrel bisulphate polymorphs. Acta Pharm 2004;54:193–204.
- Uvarov V, Popov I. Development and metroloical characterization of quantitative X-ray diffraction phase analysis for the mixtures of clopidogrel bisulphate polymorphs. J Pharm Biomed Anal 2008;46(4):676–682.
- Owens DK, Wendt RC. Estimation of the surface free energy of polymers. J Appl Polymer Sci 1969;13:1741–1747.
- Burger A, Ramberger R. Polymorphism of pharmaceuticals and other molecular crystals. I. Theory of thermodynamic rules. Mikrochim Acta 1979;2:259–271.
- Roberts SNC, Williams AC, Grimsey IM, Booth SW. Quantitative analysis of mannitol polymorphs. X-ray powder diffractometry – exploring preferred orientation effects. J Pharm Biomed Anal 2002;28:1149–1159.
- Suryanarayanan R, Herman CS. Quantitative analysis of the active tablet ingredient in multi- component tablet formulation by powder X-ray diffractometry. Int J Pharm 1991;77:287–295.
- Suryanarayanan R. Determination of the relative amounts of anhydrous carbamazapine and carbamazepine dihydrate in a mixture by powder X- ray diffraction. Pharm Res 1989;6:1017–1023.
- Suryanarayanan R. Evaluation of two concepts of crystallinity using calcium gluceptate as a model compound. Int J Pharm 1985;24:1–17.
- Phadnis NV, Suryanarayanan R. Simultaneous quantification of enantiomer and the racemic compound of ibuprofen by X-ray diffractometry. Pharm Res 1997;14:1176–1180.
- Azaroff LV, Buerger MJ. The powder method: In x-ray crystallography. New York: McGraw-Hill Book Company, Inc; 1958:255–260.
- Okumura T, Otsuka M. A novel standard sample powder preparation method for quantitative analysis of polymorphs. J Pharm Sci 2005;94:1013–1023.
- Shell JW. X-ray crystallographic applications in pharmaceutical research II. J Pharm Sci 1963;52:24–29.
- Giron D, Edel B, Piechon P. X-ray quantitative determination of polymorphism in pharmaceuticals. Mol Cryt Liq Cryst 1990;187:297–307.
- Tian F, Zhang F, Sandler N, Gordon KC, McGoverin CM, Strachan CJ, Saville DJ, Rades T. Influence of sample characteristics on quantification of carbamazepine hydrate formation by X-ray powder diffraction and Raman spectroscopy. Eur J Pharm Biopharm 2007;66:466–474.
- Klug HP, Alexander LE. X-ray diffraction procedures for polycrystalline and amorphous materials. New York: John Wiley & Sons; 1974:366–368.